I. MODIFIED AGREEMENTS
Change from original agreement
Amended deal gives Accentia worldwide rights to a topical formulation of encochleated amphotericin B; it previously had rights in the U.S. and Europe
Accentia also paid BDSI $2.5M in a move that will decrease BDSI's royalty stream by half; under the original deal in April, BDSI was to get 12%-14% royalties (9/8)
Evotec OAI AG
Biogen Idec Inc. (BIIB)
Expanded master services agreement to include the application of Evotec's EVOdevelop platform to a Biogen preclinical candidate
Evotec will provide chemical process research and development and cGMP manufacturing services for Biogen Idec; the original deal between the companies is five years old (7/19)
Pharming Group NV (the Netherlands; OTC BB:PHGUF)
Pharming gained worldwide, nonexclusive licenses to patents on nuclear transfer and associated technologies
The deal replaces earlier agreements and does not include royalty provisions; Infigen relinquished claims to any milestone payments (7/14)
Applied Imaging Corp. (ACIX)
Renewed exclusive supply deal for use of StemCell's RosetteSep reagent technology
The technology will be used to isolate circulating tumor cells in the blood of cancer patients; Applied Imaging can sell and incorporate RosetteSep products into its own products (7/20)
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
FSE = Frankfurt Stock Exchange, OTC BB = Over-The-Counter Bulletin Board.